Similar reports have been limited to the efficacy of ICL combined with bevacizumab in patients with advanced cholangiocarcinoma, hepatocellular carcinoma, and cervical carcinoma, mostly focusing on the inhibition of PD‐1 expression, ALK positivity, and EGFR mutation, and so forth [11, 12, 13, 14]. The gene discussed is ALK; the disease is hepatocellular carcinoma.